MedTrace Logo

Effects of 10 Versus 20 mL Local Anesthetic for Popliteal Plexus Block on Opioid Consumption, Pain, and Patient-Reported Outcomes After Total Knee Arthroplasty

NCT06908837 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-22

No results posted yet for this study

Summary

This trial aims to assess the analgesic effect of Popliteal Plexus Block (PPB) with 10 mL versus 20 mL of Bupivacain 5 mg/mL, when applied as an adjunct treatment to a multimodal analgesic regimen following primary total knee arthroplasty. We hypothesize that PPB with 20 mL of local anesthetic reduces 24-hour postoperative opioid consumption (= primary outcome) compared to 10 mL after TKA.

Secondary outcome include

* the frequency of 24-hour opioid-free analgesia
* pain intensity at rest and during mobilization
* Manual Muscle Tests and ability to mobilize with crutches six hours after end-of-surgery
* and patients reported outcomes using the Quality of Recovery 15 survey 24 hours after end-of-surgery.

Participant will:

* undergo primary total knee arthroplasty in spinal anesthesia.
* recieve a PPB with either 10 mL of Bupivacaine or 20 mL.
* recieve a multimodal analgesic regime including a Femoral Triangle Block.
* Have 10 scored morphine tablets available for self-administration within the first 24 postoperative hours after end-of-surgery.
* be examined by a physiotherapist 6 hours (±1 hour) after end-of-surgery to assess pain scores, manual muscle testing of ankle and knee function, and the ability to mobilize with crutches.
* complete a survey 24 hours after end-of-surgery to assess self-administered morphine intake, pain scores, and Quality of Recovery-15.

Conditions

  • Total Knee Arthroplasty
  • Regional Anesthesia
  • Multimodal Analgesic Approach
  • Postoperative Opioid-related Complications

Interventions

DRUG

Bupivacaine

Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.

Sponsors & Collaborators

  • Regionshospitalet Silkeborg

    lead OTHER

Principal Investigators

  • Johan K Sørensen, MD · Elective Surgery Centre at Silkeborg Regional Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2025-11-26
Completion
2025-11-26

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06908837 on ClinicalTrials.gov